microRNA expression in tumour tissue and plasma in patients with newly diagnosed metastatic prostate cancer

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review


  • Ahmed Hussein Zedan, University of Southern Denmark
  • ,
  • Torben Frøstrup Hansen, 2 Oncological Department, Vejle Hospital, Vejle, Denmark., University of Southern Denmark
  • ,
  • Jannie Assenholt
  • Mindaugas Pleckaitis, 5 Department of Clinical Pathology, Vejle Hospital, Vejle, Denmark.
  • ,
  • Jonna Skov Madsen
  • Palle Jörn Sloth Osther, University of Southern Denmark

Prostate cancer is the most common cancer among men in the western world. Clinical practice is continuously challenged by the pitfalls of the available diagnostic tools. microRNAs may represent promising biomarkers in many types of human cancers, including prostate cancer. The aim of this study was to investigate microRNA expression in tumour tissue and matched plasma in a cohort of patients with primary metastatic prostate cancer. The relative expression of 12 microRNAs was assessed in diagnostic needle biopsies from the prostate and matched plasma samples in two prospective cohorts (screening cohorts) comprising 21 patients with metastatic prostate cancer and 25 control patients. An independent validation cohort of plasma samples was collected prospectively from 149 newly diagnosed patients with local/locally advanced prostate cancer. Analyses were performed using real-time polymerase chain reaction. miRNA-93 showed a significant negative correlation between expression in tumour tissue and plasma in patients with metastatic prostate cancer. Furthermore, the plasma level of miRNA-93 significantly decreased after treatment in patients with local/locally advanced prostate cancer compared to baseline plasma level. The expression of six microRNAs (let-7b, miRNA-34a, -125b, -143, -145 and -221) was downregulated, and three microRNAs (miRNA-21, -25 and miRNA-93) were upregulated in tumour tissue compared to benign prostate tissue. In plasma, six microRNAs were upregulated (miRNA-21, -125b, -126, -141, -143 and -375), while let-7b was downregulated in patients with metastatic prostate cancer compared to the control cohort. In the metastatic prostate cancer cohort, the expression of four microRNAs (miRNA-125b, -126, -143 and -221), and miRNA-141 in tissue was associated with Gleason score and prostate-specific antigen, respectively. The expression of miRNA-93 in tumour tissue was correlated with matched plasma levels and showed a significant decrease in plasma level after intervention in local prostate cancer. Differential expression between tumour and benign prostate was detected for several microRNAs in both tissue and plasma.

Original languageEnglish
JournalTumor Biology
Pages (from-to)1010428318775864
Publication statusPublished - May 2018
Externally publishedYes

    Research areas

  • Aged, Biomarkers, Tumor/biosynthesis, Case-Control Studies, Cohort Studies, Gene Expression Regulation, Neoplastic, Humans, Male, MicroRNAs/biosynthesis, Middle Aged, Neoplasm Metastasis, Prostatic Neoplasms/blood

See relations at Aarhus University Citationformats

ID: 175058374